GeneOne Life Science Inc., which partnered with Inovio Pharmaceuticals Inc (NASDAQ:INO) to develop Inovio’s MERS vaccine (GLS-5300), announced the filing of an Investigational New Drug Application (IND) for GLS-5300 with the United States Food and Drug Administration. The companies expect to move the MERS vaccine into a phase I clinical trial in healthy volunteers before year end.

Middle East respiratory syndrome (MERS) is caused by a coronavirus that is related to the severe acute respiratory syndrome (SARS) virus that over 10 years ago infected over 8,000 people, with a 10% death rate. There is no vaccine or effective treatment against MERS, which spreads from human to human. Since 2012, MERS has infected over 1,500 people and killed almost 600 (40%). Recently, the largest outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea.

Earlier this year, Inovio’s MERS vaccine induced 100% protection from a live virus challenge in a preclinical study. Inovio and its collaborators evaluated its MERS vaccine in mice, camels and monkeys, or non-human primates. As published in Science Translational Medicine, the vaccine induced robust immune responses capable of preventing the virus from infecting cells in all three species. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS when challenged with a live MERS virus.

Dr. J. Joseph Kim, President and CEO, said, “We are moving rapidly from achieving complete protection from MERS in monkey studies to our goals of obtaining safety data from a phase I trial and regulatory approval.” (Original Source)

Shares of Inovio Pharmaceuticals closed last Friday at $6.23. INO has a 1-year high of $13.04 and a 1-year low of $5.32. The stock’s 50-day moving average is $6.66 and its 200-day moving average is $7.89.

On the ratings front, Inovio has been the subject of a number of recent research reports. In a report issued on September 22, Maxim Group analyst Jason McCarthy reiterated a Buy rating on INO, with a price target of $23, which implies an upside of 269.2% from current levels. Separately, on August 10, Brean Murray Carret’s Jonathan Aschoff reiterated a Buy rating on the stock and has a price target of $20.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason McCarthy and Jonathan Aschoff have a total average return of -5.9% and -4.2% respectively. McCarthy has a success rate of 53.3% and is ranked #3327 out of 3788 analysts, while Aschoff has a success rate of 37.6% and is ranked #3634.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.